PER 0.00% 13.5¢ percheron therapeutics limited

Where others have failed will Atl1102 succeed ?, page-581

  1. 267 Posts.
    lightbulb Created with Sketch. 508
    Let's see what they're going to update to PPMD...Parent Project Muscular Dystrophy has invited Sarepta Therapeutics to present details of the EMBARK clinical trial (SRP-9001-301).

    https://hotcopper.com.au/data/attachments/3680/3680662-4b9ad591788014079be3e3acfb9d8c67.jpg
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.